Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GW Pharma posts more good data from epilepsy trials

In two types of epilepsy, Dravet Syndrome and Lennox-Gastaut Syndrome, Epidiolex reduced the number of seizures compared to the placebo
picture of child
Number of seizures reduced significantly using the drug

Cannabinoid product developer GW Pharmaceuticals PLC (Nasdaq:GWPH) has revealed more good phase III data for its Epidiolex drug for epilepsy sufferers.

In two types of epilepsy, Dravet Syndrome and Lennox-Gastaut Syndrome, Epidiolex reduced the number of seizures compared to the placebo during both the 14 week treatment period and 12 week maintenance period.

 “We are pleased to present key findings from two pivotal Phase 3 studies of Epidiolex and believe these additional positive data reinforce the robust nature of the results achieved in two of the most difficult-to-treat epilepsy patient populations,” said Justin Gover, GW’s chief executive.

He added it was making good progress both towards a new drug admission for Epidiolex in the US and a commercial launch.

Orrin Devinsky, principal investigator of the Dravet syndrome trial, said he and his colleagues were excited by the prospect of prescribing an appropriately standardized and tested pharmaceutical formulation of cannabidiol.” 

“Dravet syndrome and Lennox-Gastaut syndrome are diagnosed in early childhood and represent some of the most difficult types of epilepsy to treat. 

“Nearly all patients continue to have uncontrolled seizures and other medical needs throughout their lifetime,” he said.

Shares rose 5% to US$117.6.

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects
1513583223_shutterstock_86097949.jpg
December 18 2017
VAL201 is a treatment for metastatic prostate cancer and other solid tumours
cancer cells from taken by an electron microscope
March 13 2018
Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use